School of Medicine, Chengdu University, Chengdu, Sichuan, China (mainland).
Department of Dermatology, School of Medicine, University of Colorado Denver, Aurora, CO, USA.
Med Sci Monit. 2018 Oct 25;24:7614-7624. doi: 10.12659/MSM.912735.
BACKGROUND Recent studies have illustrated that the transcription co-repressor, C-terminal binding protein 1 (CtBP1), links the metabolic alterations to transcription controls in proliferation, EMT, genome stability, metabolism, and lifespan, but whether CtBP1 affects the cellular redox homeostasis is unexplored. This study was designed to investigate the mechanism of CtBP1-mediated transcription repression that contributes to the metabolic reprogramming. MATERIAL AND METHODS Knockdown of CtBP1 in both mouse MEF cells and human melanoma cells changed cell redox homeostasis. Further, chromatin immunoprecipitation (ChIP) and luciferase reporter assay were performed for identification of CtBP1 downstream targets, pyruvate carrier 1 and 2 genes (MPC1 and MPC2), which contribute to redox homeostasis and are transcriptionally regulated by CtBP1. Moreover, blockage of the cellular NADH level with the glycolysis inhibitor 2-Deoxy-D-Glucose (2-DG) rescued MPC1 and MPC2 expression. MTT assay and scratch assay were performed to investigate the effect of MPC1 and MPC2 expression on malignant properties of melanoma cells. RESULTS The data demonstrated that CtBP1 directly bound to the promoters of MPC1 and MPC2 and transcriptionally repressed them, leading to increased levels of free NADH in the cytosol and nucleus, thus positively feeding back CtBP1's functions. Consequently, restoring MPC1 and MPC2 in human tumor cells decreases free NADH and inhibits melanoma cell proliferation and migration. CONCLUSIONS Our data indicate that MPC1 and MPC2 are principal mediators that link CtBP1-mediated transcription regulation to NADH production. The discovery of CtBP1 as an NADH regulator in addition to being an NADH sensor shows that CtBP1 is at the center of tumor metabolism and transcription control.
最近的研究表明,转录共抑制因子 C 端结合蛋白 1(CtBP1)将代谢改变与增殖、上皮间质转化、基因组稳定性、代谢和寿命中的转录控制联系起来,但 CtBP1 是否影响细胞氧化还原稳态尚不清楚。本研究旨在探讨 CtBP1 介导的转录抑制机制,该机制有助于代谢重编程。
在小鼠 MEF 细胞和人黑色素瘤细胞中敲低 CtBP1 会改变细胞氧化还原稳态。进一步进行染色质免疫沉淀(ChIP)和荧光素酶报告基因检测,以鉴定 CtBP1 的下游靶标,即丙酮酸载体 1 和 2 基因(MPC1 和 MPC2),它们有助于氧化还原稳态,并且受 CtBP1 转录调控。此外,用糖酵解抑制剂 2-脱氧-D-葡萄糖(2-DG)阻断细胞 NADH 水平可挽救 MPC1 和 MPC2 的表达。MTT assay 和划痕 assay 用于研究 MPC1 和 MPC2 表达对黑色素瘤细胞恶性特性的影响。
数据表明,CtBP1 直接结合 MPC1 和 MPC2 的启动子并转录抑制它们,导致细胞质和细胞核中游离 NADH 水平升高,从而正向反馈 CtBP1 的功能。因此,在人肿瘤细胞中恢复 MPC1 和 MPC2 可降低游离 NADH,并抑制黑色素瘤细胞增殖和迁移。
我们的数据表明,MPC1 和 MPC2 是将 CtBP1 介导的转录调节与 NADH 产生联系起来的主要介质。除了作为 NADH 传感器外,CtBP1 作为 NADH 调节剂的发现表明 CtBP1 处于肿瘤代谢和转录控制的中心。